CRISPR–Cas9 hits its target in amyloidosis

Nature Medicine explores the latest translational and clinical research news, with an analysis of Intellia and Regeneron’s gene-editing treatment, which reduced levels of transthyretin in patients. Nature Medicine explores the latest translational and clinical research news, with an analysis of Inte...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2022-12, Vol.28 (12), p.2438-2438
1. Verfasser:	Carvalho, Thiago
Format:	Artikel
Sprache:	eng
Schlagworte:	Amyloidosis Amyloidosis - genetics Biomedicine Cancer Research CRISPR CRISPR-Associated Protein 9 - metabolism CRISPR-Cas Systems - genetics Editing Gene Editing Genetic modification Humans Infectious Diseases Metabolic Diseases Molecular Medicine Neurosciences News Patients Translation Transthyretin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Nature Medicine explores the latest translational and clinical research news, with an analysis of Intellia and Regeneron’s gene-editing treatment, which reduced levels of transthyretin in patients. Nature Medicine explores the latest translational and clinical research news, with an analysis of Intellia and Regeneron’s gene-editing treatment, which reduced levels of transthyretin in patients. Image credit: Denis Pobytov / DigitalVision Vectors / Getty
ISSN:	1078-8956 1546-170X
DOI:	10.1038/d41591-022-00101-4